137 related articles for article (PubMed ID: 38657770)
1. Cost-utility analysis of adjunct repetitive transcranial magnetic stimulation for treatment resistant bipolar depression.
Chatterton ML; Lee YY; Le LK; Nichols M; Carter R; Berk M; Mihalopoulos C
J Affect Disord; 2024 Jul; 356():639-646. PubMed ID: 38657770
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness of Repetitive Transcranial Magnetic Stimulation versus Antidepressant Therapy for Treatment-Resistant Depression.
Nguyen KH; Gordon LG
Value Health; 2015 Jul; 18(5):597-604. PubMed ID: 26297087
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of electroconvulsive therapy compared to repetitive transcranial magnetic stimulation for treatment-resistant severe depression: a decision model.
Vallejo-Torres L; Castilla I; González N; Hunter R; Serrano-Pérez P; Perestelo-Pérez L
Psychol Med; 2015 May; 45(7):1459-70. PubMed ID: 25354790
[TBL] [Abstract][Full Text] [Related]
4. Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Depression: An Economic Analysis.
Health Quality Ontario
Ont Health Technol Assess Ser; 2016; 16(6):1-51. PubMed ID: 27110317
[TBL] [Abstract][Full Text] [Related]
5. Cost-utility analysis of curative and maintenance repetitive transcranial magnetic stimulation (rTMS) for treatment-resistant unipolar depression: a randomized controlled trial protocol.
Bulteau S; Laurin A; Volteau C; Dert C; Lagalice L; Schirr-Bonnans S; Bukowski N; Guitteny M; Simons L; Cabelguen C; Pichot A; Tessier F; Bonnin A; Lepage A; ; ; Vanelle JM; Sauvaget A; Riche VP
Trials; 2020 Apr; 21(1):312. PubMed ID: 32248820
[TBL] [Abstract][Full Text] [Related]
6. Cost-Utility Analysis of Electroconvulsive Therapy and Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Depression in Ontario.
Fitzgibbon KP; Plett D; Chan BCF; Hancock-Howard R; Coyte PC; Blumberger DM
Can J Psychiatry; 2020 Mar; 65(3):164-173. PubMed ID: 31801363
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness Modeling of Repetitive Transcranial Magnetic Stimulation Compared to Electroconvulsive Therapy for Treatment-Resistant Depression in Singapore.
Zhao YJ; Tor PC; Khoo AL; Teng M; Lim BP; Mok YM
Neuromodulation; 2018 Jun; 21(4):376-382. PubMed ID: 29143405
[TBL] [Abstract][Full Text] [Related]
8. Implementation of intermittent theta burst stimulation compared to conventional repetitive transcranial magnetic stimulation in patients with treatment resistant depression: A cost analysis.
Mendlowitz AB; Shanbour A; Downar J; Vila-Rodriguez F; Daskalakis ZJ; Isaranuwatchai W; Blumberger DM
PLoS One; 2019; 14(9):e0222546. PubMed ID: 31513675
[TBL] [Abstract][Full Text] [Related]
9. Repetitive Transcranial Magnetic Stimulation for People With Treatment-Resistant Depression: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2021; 21(4):1-232. PubMed ID: 34055112
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of transcranial magnetic stimulation in the treatment of major depression: a health economics analysis.
Simpson KN; Welch MJ; Kozel FA; Demitrack MA; Nahas Z
Adv Ther; 2009 Mar; 26(3):346-68. PubMed ID: 19330495
[TBL] [Abstract][Full Text] [Related]
11. [Health-related quality of life assessment in depression after low-frequency transcranial magnetic stimulation].
Dumas R; Boyer L; Richieri R; Guedj E; Auquier P; Lançon C
Encephale; 2014 Feb; 40(1):74-80. PubMed ID: 24091070
[TBL] [Abstract][Full Text] [Related]
12. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
[TBL] [Abstract][Full Text] [Related]
13. A Non-inferiority Framework for Cost-Effectiveness Analysis.
Xie X; Falk L; Brophy JM; Tu HA; Guo J; Gajic-Veljanoski O; Sikich N; Dhalla IA; Ng V
Int J Technol Assess Health Care; 2019; 35(4):291-297. PubMed ID: 31337452
[TBL] [Abstract][Full Text] [Related]
14. The clinical effectiveness and cost of repetitive transcranial magnetic stimulation versus electroconvulsive therapy in severe depression: a multicentre pragmatic randomised controlled trial and economic analysis.
McLoughlin DM; Mogg A; Eranti S; Pluck G; Purvis R; Edwards D; Landau S; Brown R; Rabe-Heskith S; Howard R; Philpot M; Rothwell J; Romeo R; Knapp M
Health Technol Assess; 2007 Jul; 11(24):1-54. PubMed ID: 17580003
[TBL] [Abstract][Full Text] [Related]
15. Repetitive transcranial magnetic stimulation may be a cost-effective alternative to antidepressant therapy after two treatment failures in patients with major depressive disorder.
Zemplényi A; Józwiak-Hagymásy J; Kovács S; Erdősi D; Boncz I; Tényi T; Osváth P; Voros V
BMC Psychiatry; 2022 Jun; 22(1):437. PubMed ID: 35764989
[TBL] [Abstract][Full Text] [Related]
16. The cost-effectiveness of lamotrigine in the maintenance treatment of adults with bipolar I disorder.
Calvert NW; Burch SP; Fu AZ; Reeves P; Thompson TR
J Manag Care Pharm; 2006 May; 12(4):322-30. PubMed ID: 16792438
[TBL] [Abstract][Full Text] [Related]
17. The population cost-effectiveness of delivering universal and indicated school-based interventions to prevent the onset of major depression among youth in Australia.
Lee YY; Barendregt JJ; Stockings EA; Ferrari AJ; Whiteford HA; Patton GA; Mihalopoulos C
Epidemiol Psychiatr Sci; 2017 Oct; 26(5):545-564. PubMed ID: 27509769
[TBL] [Abstract][Full Text] [Related]
18. Internet-Delivered Cognitive Behavioural Therapy for Major Depression and Anxiety Disorders: A Health Technology Assessment.
Health Quality Ontario
Ont Health Technol Assess Ser; 2019; 19(6):1-199. PubMed ID: 30873251
[TBL] [Abstract][Full Text] [Related]
19. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
20. The cost-effectiveness of cognitive behavioral therapy for bulimia nervosa in the Australian context.
Le LK; Hay P; Wade T; Touyz S; Mihalopoulos C
Int J Eat Disord; 2017 Dec; 50(12):1367-1377. PubMed ID: 29044626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
